Skip to main content

Glucotrol XL Side Effects

Generic name: glipizide

Medically reviewed by Drugs.com. Last updated on Jun 21, 2021.

Note: This document contains side effect information about glipizide. Some of the dosage forms listed on this page may not apply to the brand name Glucotrol XL.

For the Consumer

Applies to glipizide: oral tablets

Side effects include:

Conventional tablets: Nausea, anorexia, vomiting, pyrosis, gastralgia, diarrhea, constipation.

Extended-release tablets: Dizziness, diarrhea, nervousness, tremor, hypoglycemia, flatulence.

Glipizide (the active ingredient contained in Glucotrol XL) metformin hydrochloride fixed combination: Upper respiratory tract infection, diarrhea, dizziness, hypertension, nausea/vomiting, musculoskeletal pain, headache, abdominal pain, urinary tract infection.

For Healthcare Professionals

Applies to glipizide: compounding powder, oral tablet, oral tablet extended release

General

The more commonly reported side effects have included dizziness, diarrhea, nervousness, tremor, hypoglycemia, and flatulence.[Ref]

Metabolic

Disulfiram-like reactions have been reported with sulfonylureas. Clinical experience has shown this drug to have a low incidence of disulfiram-like alcohol reactions.[Ref]

Common (1% to 10%): Hypoglycemia

Uncommon (less than 1%): Thirst

Frequency not reported: Disulfiram like reactions, hepatic porphyria, hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), elevation of LDH[Ref]

Hematologic

Frequency not reported: Leucopenia, agranulocytosis, thrombocytopenia, aplastic anemia, hemolytic anemia, pancytopenia[Ref]

Cardiovascular

Common (1% to 10%): Syncope

Uncommon (less than 1%): Arrhythmia, flushing, hypertension[Ref]

Hepatic

Frequency not reported: Impaired hepatic function, hepatitis, jaundice, mild to moderate ALT, LDH, alkaline phosphatase elevations

Postmarketing reports: Cholestatic and hepatocellular forms of liver injury accompanied by jaundice[Ref]

Dermatologic

Dermatologic side effects frequently disappear with continued therapy. Photosensitivity has been reported with other sulfonylureas.[Ref]

Common (1% to 10%): Sweating, pruritus

Uncommon (less than 1%): Rash, urticaria

Frequency not reported: Rash, erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, eczema[Ref]

Gastrointestinal

Common (1% to 10%): Nausea, diarrhea, constipation, gastralgia, vomiting, flatulence, dyspepsia

Uncommon (less than 1%): Anorexia, trace blood in stool

Frequency not reported: Gastrointestinal irritation, gastrointestinal bleeding

Postmarketing reports: Abdominal pain[Ref]

Gastrointestinal side effects appear to be dose-related and may disappear on division or reduction of dosage.[Ref]

Genitourinary

Common (1% to 10%): Polyuria

Uncommon (less than 1%): Dysuria[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia, leg cramps, myalgia[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness, nervousness, tremors, paresthesia, hypesthesia

Uncommon (less than 1%): Migraine

Frequency not reported: Drowsiness[Ref]

Ocular

Common (1% to 10%): Blurred vision

Uncommon (less than 1%): Pain in the eye, conjunctivitis, retinal hemorrhage

Frequency not reported: Diplopia, abnormal vision, visual impairment, decreased vision[Ref]

Other

Common (1% to 10%): Asthenia, pain

Uncommon (less than 1%): Chills, edema

Frequency not reported: Vertigo, malaise[Ref]

Psychiatric

Common (1% to 10%): Insomnia, anxiety, depression

Frequency not reported: Confusion[Ref]

Respiratory

Common (1% to 10%): Rhinitis

Uncommon (less than 1%): Pharyngitis, dyspnea[Ref]

Renal

Frequency not reported: Mild to moderate BUN and creatinine elevations

References

1. "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals (2002):

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

4. Lebovitz HE, Feinglos MN "Long-term safety and efficacy of glipizide." Am J Med 75 (1983): 60-6

5. Schwenk NM, Moder KG "A coproporphyria-like syndrome induced by glipizide." Mayo Clin Proc 66 (1991): 312-6

6. Asplund K, Lundman B, Wiholm BE "Severe hypoglycaemia during treatment with glipizide." Diabet Med 8 (1991): 726-31

7. Avery GS, Brogden RN, Heel RC, Pakes GE, Speight TM "Glipizide: a review of its pharmacological properties and therapeutic use." Drugs 18 (1979): 329-53

8. Lebovitz HE "Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use." Pharmacotherapy 5 (1985): 63-77

9. Prendergast BD "Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents." Clin Pharm 3 (1984): 473-85

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.